Crospovidone XL 10 is a crosslinked, water-insoluble form of polyvinylpyrrolidone used primarily as a tablet superdisintegrant. I use the term “superdisintegrant” because its main purpose is to help a compressed tablet break apart rapidly after contact with gastrointestinal fluids, allowing the active pharmaceutical ingredient to become available for dissolution. In many immediate-release formulations, crospovidone may be used at approximately 0.5% to 5% w/w, although the appropriate level depends on the drug, excipients, manufacturing process, and target performance.
For pharmaceutical buyers, the key point is that Crospovidone XL 10 is not usually selected as the active ingredient or a conventional binder. It is selected to improve tablet breakup through rapid liquid uptake and a porous, swelling-limited action. The exact suitability of an XL 10 grade should be confirmed through its technical data sheet, certificate of analysis, compatibility assessment, and formulation trials before commercial approval.
Crospovidone is a crosslinked homopolymer of N-vinyl-2-pyrrolidone, also known as crosslinked polyvinylpyrrolidone or crosslinked PVP. Unlike soluble PVP grades, crosslinked crospovidone does not dissolve readily in water. Instead, its particle structure allows it to draw liquid into the tablet and promote rapid physical breakup.
The designation “XL 10” generally identifies a particular commercial grade or particle-size classification within a supplier’s crospovidone portfolio. However, grade names are not automatically interchangeable between manufacturers. When I evaluate a material for a buyer, I recommend checking the supplier’s stated particle-size distribution, moisture, bulk density, flow characteristics, residue requirements, and applicable quality documentation rather than relying on the grade name alone.
The primary function of Crospovidone XL 10 is to accelerate disintegration. When a tablet contacts water or gastrointestinal fluid, the crospovidone particles promote liquid penetration through capillary action. This weakens the compact and helps it separate into smaller granules or particles, which can support subsequent drug dissolution.
Crospovidone is often valued because it can provide effective disintegration without the same degree of visible gel formation associated with some highly swelling disintegrants. Nevertheless, performance depends on particle size, distribution within the tablet, compression force, lubricant level, tablet porosity, and the properties of the active ingredient.
A tablet must allow liquid to enter its internal structure before it can disintegrate efficiently. Crospovidone can contribute to wicking, meaning that liquid moves through pores and channels within the compact. This function is especially relevant when a formulation contains poorly wetting powders or when the manufacturing process produces a relatively dense tablet.
For this reason, Crospovidone XL 10 may be added either intragranularly, extragranularly, or through a combination of both approaches. The best distribution is formulation-specific. Extragranular addition can place the superdisintegrant closer to the tablet’s external structure, while intragranular addition may support breakup of granules; the balance should be established through comparative trials.
Crospovidone does not directly increase the solubility of every active pharmaceutical ingredient. Its contribution is indirect: faster tablet breakup can increase the surface area available for dissolution. If the drug is poorly soluble, however, a faster disintegration time alone may not deliver the desired dissolution profile, so particle engineering, wetting agents, solid dispersion technology, or other approaches may also be required.
Crospovidone XL 10 is commonly considered for immediate-release tablets where rapid and consistent disintegration is important. Potential applications include conventional oral tablets, chewable tablets, orally disintegrating formulations, and selected direct-compression or dry-granulation systems. The final use depends on regulatory requirements and the performance target established for the finished product.
These are application categories rather than performance guarantees. A formulation team should compare disintegration and dissolution results at different use levels and processing conditions. For many immediate-release products, a pharmacopeial disintegration specification may be set around 15 minutes, but the applicable limit depends on the dosage form, monograph, market, and product specification.
Yuking are exported all over the world and different industries with quality first. Our belief is to provide our customers with more and better high value-added products. Let's create a better future together.
A practical starting point is often a screening range such as 0.5% to 5% of tablet weight, followed by optimization. A low level may be sufficient for a porous, readily wettable formulation, while a denser or more hydrophobic system may require a different level or a different excipient combination. Increasing the concentration indefinitely is not a reliable solution because it can affect tablet size, dilution of the active, flow, compactability, and cost.
In wet granulation, the superdisintegrant may be divided between the granulation phase and the final blending phase. In direct compression, it is typically blended with the other powders before compression, subject to the manufacturer’s process design. I recommend comparing at least two placement strategies when disintegration is a critical quality attribute.
Compression force can influence tablet porosity and therefore liquid penetration. Excessive compression may produce a strong but slow-disintegrating tablet, while insufficient compression can increase friability and handling losses. Lubrication also deserves attention because excessive hydrophobic lubricant or prolonged blending may reduce wetting and interfere with disintegration.
When purchasing Crospovidone XL 10, I recommend reviewing more than the product name. The buyer should request the current specification and a representative certificate of analysis for the exact manufacturing grade. Important parameters may include identification, assay or polymer-related requirements, moisture or loss on drying, residue on ignition, particle-size distribution, bulk density, microbial quality where applicable, and packaging information.
| Evaluation area | Why it matters |
|---|---|
| Particle-size distribution | May influence flow, blend uniformity, liquid penetration, and disintegration behavior. |
| Moisture content | Can affect powder handling, stability assessment, and compression behavior. |
| Bulk density and flow | Relevant to hopper feeding, blending, die filling, and direct compression. |
| Microbial and chemical quality | Supports raw-material qualification and compliance with the buyer’s quality system. |
| Packaging and storage | Helps protect the powder from moisture, contamination, and handling damage. |
Because “XL 10” can be supplier-specific, I do not recommend approving a replacement solely from a similar label. A buyer should compare functional performance, not only identity testing. Side-by-side trials should normally include blend behavior, tablet hardness, friability, disintegration, dissolution, and stability-related observations.
The correct crospovidone grade depends on the complete formulation and process. Buyers should consider the active ingredient’s solubility, dose, particle size, hygroscopicity, and compatibility with the excipient. They should also consider whether the product uses direct compression, wet granulation, dry granulation, or a specialized orally disintegrating tablet process.
Supply reliability is equally important for commercial pharmaceutical production. I suggest confirming minimum order quantity, standard pack size, production capacity, batch consistency, documentation lead time, export packaging, storage conditions, and change-control procedures. If the material is intended for a regulated product, the supplier should be able to explain its quality system and provide appropriate technical documents without making unsupported claims.
At Yuking, I understand that a B2B buyer needs more than a material quotation. The purchasing decision normally involves technical evaluation, sample planning, documentation review, logistics coordination, and commercial continuity. We can discuss the intended dosage form, manufacturing process, target market, packaging needs, and required documents so that the proposed Crospovidone XL 10 supply is evaluated against the actual project.
Our support can include product information, sample coordination, specification review, certificate-of-analysis discussion, export packing options, and order planning. Where a buyer is comparing grades, I recommend a controlled technical comparison rather than an assumption that all crospovidone products will behave identically. Final approval should remain with the buyer’s formulation, quality, and regulatory teams.
Crospovidone XL 10 is used in tablets primarily to promote rapid and reliable disintegration, improve liquid penetration, and support the dissolution process after the tablet breaks apart. It is especially relevant when a manufacturer is developing immediate-release or orally disintegrating products and needs to balance tablet strength with rapid breakup.
The next step is to define your tablet type, process, target disintegration time, active-ingredient characteristics, and documentation requirements. I can help you review the required Crospovidone XL 10 specification, arrange a suitable sample or quotation, and discuss supply conditions for your project. Contact Yuking with your intended application and purchasing requirements so we can support a practical, evidence-based raw-material evaluation.
If you want to learn more, please visit our website crospovidone xl 10.